|
1
|
Baxter NN, Whitson BA and Tuttle TM:
Trends in the treatment and outcome of pancreatic cancer in the
United States. Ann Surg Oncol. 14:1320–1326. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Beger HG, Rau B, Gansauge F, Leder G,
Schwarz M and Poch B: Pancreatic Cancer - Low Survival Rates. Dtsch
Arztebl Int. 105:255–262. 2008.PubMed/NCBI
|
|
3
|
Ducreux M, Cuhna AS, Caramella C,
Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van
Laethem JL, Conroy T, et al ESMO Guidelines Committee, : Cancer of
the pancreas: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 26 (Suppl 5):v56–v68. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneider G, Siveke JT, Eckel F and Schmid
RM: Pancreatic cancer: Basic and clinical aspects.
Gastroenterology. 128:1606–1625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sirri E, Castro FA, Kieschke J, Jansen L,
Emrich K, Gondos A, Holleczek B, Katalinic A, Urbschat I, Vohmann
C, et al: Recent Trends in Survival of Patients With Pancreatic
Cancer in Germany and the United States. Pancreas. 45:908–914.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minicozzi P, Cassetti T, Vener C and Sant
M: Analysis of incidence, mortality and survival for pancreatic and
biliary tract cancers across Europe, with assessment of influence
of revised European age standardisation on estimates. Cancer
Epidemiol. 55:52–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cleary SP, Gryfe R, Guindi M, Greig P,
Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, et
al: Prognostic factors in resected pancreatic adenocarcinoma:
Analysis of actual 5-year survivors. J Am Coll Surg. 198:722–731.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khorana AA, Mangu PB, Berlin J,
Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R,
Shapiro M, et al: Potentially Curable Pancreatic Cancer: American
Society of Clinical Oncology Clinical Practice Guideline. J Clin
Oncol. 34:2541–2556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bramhall SR, Allum WH, Jones AG, Allwood
A, Cummins C and Neoptolemos JP: Treatment and survival in 13,560
patients with pancreatic cancer, and incidence of the disease, in
the West Midlands: An epidemiological study. Br J Surg. 82:111–115.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim JE, Chien MW and Earle CC: Prognostic
factors following curative resection for pancreatic adenocarcinoma:
A population-based, linked database analysis of 396 patients. Ann
Surg. 237:74–85. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raut CP, Tseng JF, Sun CC, Wang H, Wolff
RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, et al:
Impact of resection status on pattern of failure and survival after
pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg.
246:52–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rossi ML, Rehman AA and Gondi CS:
Therapeutic options for the management of pancreatic cancer. World
J Gastroenterol. 20:11142–11159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Müller PC, Frey MC, Ruzza CM, Nickel F,
Jost C, Gwerder C, Hackert T, Z'graggen K and Kessler U:
Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the
Current High-Level Evidence. Pharmacology. 1–11. 2020.doi:
10.1159/000510343. View Article : Google Scholar
|
|
15
|
Ren B, Cui M, Yang G, Wang H, Feng M, You
L and Zhao Y: Tumor microenvironment participates in metastasis of
pancreatic cancer. Mol Cancer. 17:1082018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spratt JS, Edwards M, Kubota T, Lindberg R
and Tseng MT: Peritoneal carcinomatosis: Anatomy, physiology,
diagnosis, management. Curr Probl Cancer. 10:553–584. 1986.
View Article : Google Scholar
|
|
17
|
Sugarbaker PH: Observations concerning
cancer spread within the peritoneal cavity and concepts supporting
an ordered pathophysiology. Principles of Management. Cancer
Treatment and Research. 82. Springer; Boston, MA: pp. 79–100. 1996,
View Article : Google Scholar
|
|
18
|
del Castillo CF and Warshaw L: Peritoneal
metastases in pancreatic carcinoma. Hepatogastroenterology.
40:430–432. 1993.PubMed/NCBI
|
|
19
|
Yachida S and Iacobuzio-Donahue CA: The
pathology and genetics of metastatic pancreatic cancer. Arch Pathol
Lab Med. 133:413–422. 2009.PubMed/NCBI
|
|
20
|
Hishinuma S, Ogata Y, Matsui J and Ozawa
I: Results of surgery and adjuvant radiotherapy for pancreatic
cancer. J Hepatobiliary Pancreat Surg. 5:143–150. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sugarbaker P: An overview of
peritonectomy, visceral resections, and perioperative chemotherapy
for peritoneal surface malignancy. Cytoreductive Surgery and
Perioperative Chemotherapy for Peritoneal Surface Malignancy.
Ciné-Med, Inc.; Woodbury, CT, USA: pp. 1–30. 2012
|
|
22
|
Chua TC, Moran BJ, Sugarbaker PH, Levine
EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, et
al: Early- and long-term outcome data of patients with pseudomyxoma
peritonei from appendiceal origin treated by a strategy of
cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy. J Clin Oncol. 30:2449–2456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van Driel WJ, Koole SN, Sikorska K,
Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT,
van der Velden J, Arts HJ, Massuger LFAG, et al: Hyperthermic
Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med.
378:230–240. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan TD, Deraco M, Baratti D, Kusamura S,
Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, et al:
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
for malignant peritoneal mesothelioma: Multi-institutional
experience. J Clin Oncol. 27:6237–6242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sugarbaker PH: New standard of care for
appendiceal epithelial neoplasms and pseudomyxoma peritonei
syndrome? Lancet Oncol. 7:69–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elias D, Blot F, El Otmany A, Antoun S,
Lasser P, Boige V, Rougier P and Ducreux M: Curative treatment of
peritoneal carcinomatosis arising from colorectal cancer by
complete resection and intraperitoneal chemotherapy. Cancer.
92:71–76. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Verwaal VJ, Bruin S, Boot H, van Slooten G
and van Tinteren H: 8-year follow-up of randomized trial:
Cytoreduction and hyperthermic intraperitoneal chemotherapy versus
systemic chemotherapy in patients with peritoneal carcinomatosis of
colorectal cancer. Ann Surg Oncol. 15:2426–2432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Verwaal VJ, van Ruth S, de Bree E, van
Sloothen GW, van Tinteren H, Boot H and Zoetmulder FA: Randomized
trial of cytoreduction and hyperthermic intraperitoneal
chemotherapy versus systemic chemotherapy and palliative surgery in
patients with peritoneal carcinomatosis of colorectal cancer. J
Clin Oncol. 21:3737–3743. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beeharry MK, Zhu Z-L, Liu W-T, Yao X–X,
Yan M and Zhu Z-G: Prophylactic HIPEC with radical D2 gastrectomy
improves survival and peritoneal recurrence rates for locally
advanced gastric cancer: Personal experience from a randomized case
control study. BMC Cancer. 19:932. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang X-J, Huang C-Q, Suo T, Mei LJ, Yang
GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y and Li Y: Cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy improves
survival of patients with peritoneal carcinomatosis from gastric
cancer: Final results of a phase III randomized clinical trial. Ann
Surg Oncol. 18:1575–1581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate health care
interventions: explanation and elaboration. PLoS Med.
6:e10001002009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement. BMJ. 339:b25352009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Higgins JP, Altman DG and Sterne JA:
Assessing risk of bias in included studies. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0. Higgins JP and
Green S; The Cochrane Collaboration, : https://handbook-5-1.cochrane.orgOctober 17–2019
View Article : Google Scholar
|
|
34
|
Tentes A-A, Stamou K, Pallas N, Karamveri
C, Kyziridis D and Hristakis C: The effect of hyperthermic
intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant
in patients with resectable pancreatic cancer. Int J Hyperthermia.
32:895–899. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tentes A-A, Pallas N, Karamveri C,
Kyziridis D and Hristakis C: Cytoreduction and HIPEC for peritoneal
carcinomatosis of pancreatic cancer. J BUON. 23:482–487.
2018.PubMed/NCBI
|
|
36
|
Farma JM, Pingpank JF, Libutti SK,
Bartlett DL, Ohl S, Beresneva T and Alexander HR: Limited survival
in patients with carcinomatosis from foregut malignancies after
cytoreduction and continuous hyperthermic peritoneal perfusion. J
Gastrointest Surg. 9:1346–1353. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fujimura T, Yonemura Y, Fujita H, Michiwa
Y, Kawamura T, Nojima N, Sato T, Fushida S, Nishimura G, Miwa K, et
al: Chemohyperthermic peritoneal perfusion for peritoneal
dissemination in various intra-abdominal malignancies. Int Surg.
84:60–66. 1999.PubMed/NCBI
|
|
38
|
Thomassen I, Lemmens VE, Nienhuijs SW,
Luyer MD, Klaver YL and de Hingh IH: Incidence, prognosis, and
possible treatment strategies of peritoneal carcinomatosis of
pancreatic origin: A population-based study. Pancreas. 42:72–75.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Conlon KC, Dougherty E, Klimstra DS, Coit
DG, Turnbull AD and Brennan MF: The value of minimal access surgery
in the staging of patients with potentially resectable
peripancreatic malignancy. Ann Surg. 223:134–140. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Merchant NB and Conlon KC: Laparoscopic
evaluation in pancreatic cancer. Semin Surg Oncol. 15:155–165.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vargas R, Nino-Murcia M, Trueblood W and
Jeffrey RB Jr: MDCT in Pancreatic adenocarcinoma: Prediction of
vascular invasion and resectability using a multiphasic technique
with curved planar reformations. AJR Am J Roentgenol. 182:419–425.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
González-Moreno S, González-Bayón LA and
Ortega-Pérez G: Hyperthermic intraperitoneal chemotherapy:
Rationale and technique. World J Gastrointest Oncol. 2:68–75. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Harmon RL and Sugarbaker PH: Prognostic
indicators in peritoneal carcinomatosis from gastrointestinal
cancer. Int Semin Surg Oncol. 2:32005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Portilla AG, Sugarbaker PH and Chang D:
Second-look surgery after cytoreduction and intraperitoneal
chemotherapy for peritoneal carcinomatosis from colorectal cancer:
Analysis of prognostic features. World J Surg. 23:23–29. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sugarbaker PH and Chang D: Results of
treatment of 385 patients with peritoneal surface spread of
appendiceal malignancy. Ann Surg Oncol. 6:727–731. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
HIPEC as Neoadjuvant Treatment for
Resectable Pancreatic Adenocarcinoma. NCT02850874. Clinicaltrials.govJuly 28–2019
|
|
47
|
Intrabdominal Hyperthermic Chemotherapy
and Pancreatic Cancer. NCT03251365. Clinicaltrials.govJuly 28–2019
|
|
48
|
Péron J, Giai J, Maucort-Boulch D and
Buyse M: The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic
Pancreatic Adenocarcinoma. Pancreas. 48:275–280. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Klaver CEL, Wisselink DD, Punt CJA,
Snaebjornsson P, Crezee J, Aalbers AGJ, Brandt A, Bremers AJA,
Burger JWA, Fabry HFJ, et al COLOPEC collaborators group, :
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with
locally advanced colon cancer (COLOPEC): A multicentre, open-label,
randomised trial. Lancet Gastroenterol Hepatol. 4:761–770. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Quenet F, Elias D, Roca L, Goere D, Ghouti
L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, et al: A
UNICANCER phase III trial of hyperthermic intra-peritoneal
chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC):
PRODIGE 7. J Clin Oncol. 36 (Suppl. 18):LBA3503. 2018. View Article : Google Scholar
|
|
51
|
Goéré D, Glehen O, Quenet F, Guilloit JM,
Bereder JM, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech JJ,
et al BIG-RENAPE group, : Second-look surgery plus hyperthermic
intraperitoneal chemotherapy versus surveillance in patients at
high risk of developing colorectal peritoneal metastases
(PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study. Lancet
Oncol. 21:1147–1154. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Koh CE, Ansari N, Morris D and Moran B;
Australian and New Zealand Peritoneal Malignancy Collaborative (ANZ
PMC), : Beware mis-representation of PRODIGE 7: Danger of throwing
out the cytoreductive surgery baby with the hyperthermic
intraperitoneal chemotherapy bathwater. ANZ J Surg. 89:992–994.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nagourney RA, Evans S, Tran PH, Nagourney
AJ and Sugarbaker PH: Colorectal cancer cells from patients treated
with FOLFOX or CAPOX are resistant to oxaliplatin. Eur J Surg
Oncol. S0748-7983(20)30789-7. 2020.doi: 10.1016/j.ejso.2020.09.017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lei ZY, Guan TP, Luo JL, Tang HS and Cui
SZ: Rationality of performing hyperthermic intraperitoneal
chemotherapy 5–8 weeks after primary tumor resection for patients
with locally advanced colorectal cancer-based on COLOPEC. Zhonghua
Wei Chang Wai Ke Za Zhi. 22:1115–1117. 2019.(In Chinese).
PubMed/NCBI
|
|
55
|
Segura-Sampedro JJ and Morales-Soriano R:
Prophylactic HIPEC with oxaliplatin might be of benefit in T4 and
perforated colon cancer: Another possible interpretation of the
COLOPEC results. Rev Esp Enferm Dig. 112:6662020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lim MC, Chang S-J, Yoo HJ, Nam B-H,
Bristow R and Park S-Y: Randomized trial of hyperthermic
intraperitoneal chemotherapy (HIPEC) in women with primary advanced
peritoneal, ovarian, and tubal cancer. J Clin Oncol. 35 (Suppl
15):5520. 2017. View Article : Google Scholar
|
|
57
|
de Bree E and Michelakis D: An overview
and update of hyperthermic intraperitoneal chemotherapy in ovarian
cancer. Expert Opin Pharmacother. 21:1479–1492. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fotopoulou C, Sehouli J, Mahner S, Harter
P, Van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L and
Du Bois A: HIPEC: HOPE or HYPE in the fight against advanced
ovarian cancer? Ann Oncol. 29:1610–1613. 2018. View Article : Google Scholar : PubMed/NCBI
|
